Welcome!

News Feed Item

Lumbar Spinal Stenosis Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 5, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Lumbar Spinal Stenosis Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02256136/Lumbar-Spinal-Stenosis-Global-Clinical-Trials-Review-H2-2014.html

Lumbar Spinal Stenosis Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Lumbar Spinal Stenosis Global Clinical Trials Review, H2, 2014" provides data on the Lumbar Spinal Stenosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lumbar Spinal Stenosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lumbar Spinal Stenosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Lumbar Spinal Stenosis 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11

Top Countries Contributing to Clinical Trials in Central and South America 12
Clinical Trials by G7 Countries: Proportion of Lumbar Spinal Stenosis to Central Nervous System Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Lumbar Spinal Stenosis to Central Nervous System Clinical Trials 16
Clinical Trials by Phase in E7 Countries 17
Clinical Trials by Phase 18
In Progress Trials by Phase 19
Clinical Trials by Trial Status 20
Clinical Trials by End Point Status 21
Unaccomplished Trials of Lumbar Spinal Stenosis 22
Subjects Recruited Over a Period of Time 23
Clinical Trials by Sponsor Type 24
Prominent Sponsors 25
Top Companies Participating in Lumbar Spinal Stenosis Therapeutics Clinical Trials 26
Prominent Drugs 27
Clinical Trial Profiles 28

Clinical Trial Overview of Top Companies 28
Sucampo Pharmaceuticals, Inc. 28
Clinical Trial Overview of Sucampo Pharmaceuticals, Inc. 28
United Therapeutics Corporation 29
Clinical Trial Overview of United Therapeutics Corporation 29
Mesoblast Limited 30
Clinical Trial Overview of Mesoblast Limited 30
KT&G Corporation 31
Clinical Trial Overview of KT&G Corporation 31
Kaken Pharmaceutical Co., Ltd. 32
Clinical Trial Overview of Kaken Pharmaceutical Co., Ltd. 32
Clinical Trial Overview of Top Institutes / Government 33
Keio University 33
Clinical Trial Overview of Keio University 33
Hamamatsu University School of Medicine 34
Clinical Trial Overview of Hamamatsu University School of Medicine 34
National University Of Health Sciences 35
Clinical Trial Overview of National University Of Health Sciences 35

University of Manitoba 36
Clinical Trial Overview of University of Manitoba 36
Asan Medical Center 37
Clinical Trial Overview of Asan Medical Center 37
Kobe University 38
Clinical Trial Overview of Kobe University 38
Yonsei University 39
Clinical Trial Overview of Yonsei University 39
Ohio State University 40
Clinical Trial Overview of Ohio State University 40
Leiden University Medical Center 41
Clinical Trial Overview of Leiden University Medical Center 41
Emory University 42
Clinical Trial Overview of Emory University 42
Five Key Clinical Profiles 43
Appendix 65
Abbreviations 65
Definitions 65
Research Methodology 66
Secondary Research 66
About GlobalData 67
Contact Us 67
Disclaimer 67
Source 67

List of Tables

Lumbar Spinal Stenosis Therapeutics, Global, Clinical Trials by Region, 2014* 6
Lumbar Spinal Stenosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Lumbar Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Europe, Top Countries, 2014* 10
Lumbar Spinal Stenosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 12
Proportion of Lumbar Spinal Stenosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Lumbar Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Lumbar Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Lumbar Spinal Stenosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Lumbar Spinal Stenosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 17
Lumbar Spinal Stenosis Therapeutics, Global, Clinical Trials by Phase, 2014* 18

Lumbar Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 19
Lumbar Spinal Stenosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 20
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 21
Lumbar Spinal Stenosis Therapeutics, Global, Terminated Clinical Trials, 2014* 22
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23
Lumbar Spinal Stenosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 24
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Sucampo Pharmaceuticals, Inc., 2014* 28
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by United Therapeutics Corporation, 2014* 29

Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Mesoblast Limited, 2014* 30
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by KT&G Corporation, 2014* 31
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Kaken Pharmaceutical Co., Ltd., 2014* 32
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Keio University, 2014* 33
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Hamamatsu University School of Medicine, 2014* 34
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National University Of Health Sciences, 2014* 35
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Manitoba, 2014* 36
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Asan Medical Center, 2014* 37
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Kobe University, 2014* 38
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Yonsei University, 2014* 39
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Ohio State University, 2014* 40
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Leiden University Medical Center, 2014* 41
Lumbar Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Emory University, 2014* 42

List of Figures

Lumbar Spinal Stenosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Lumbar Spinal Stenosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Lumbar Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 9
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Europe, Top Countries (%), 2014* 10
Lumbar Spinal Stenosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 11
Proportion of Lumbar Spinal Stenosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Lumbar Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Lumbar Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Lumbar Spinal Stenosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Lumbar Spinal Stenosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 17
Lumbar Spinal Stenosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 18
Lumbar Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 19
Lumbar Spinal Stenosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 20
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23
Lumbar Spinal Stenosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 24
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Lumbar Spinal Stenosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
GlobalData Methodology 66

To order this report: Lumbar Spinal Stenosis Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02256136/Lumbar-Spinal-Stenosis-Global-Clinical-Trials-Review-H2-2014.html

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
With billions of sensors deployed worldwide, the amount of machine-generated data will soon exceed what our networks can handle. But consumers and businesses will expect seamless experiences and real-time responsiveness. What does this mean for IoT devices and the infrastructure that supports them? More of the data will need to be handled at - or closer to - the devices themselves.
Grape Up is a software company, specialized in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market across the USA and Europe, we work with a variety of customers from emerging startups to Fortune 1000 companies.
The age of Digital Disruption is evolving into the next era – Digital Cohesion, an age in which applications securely self-assemble and deliver predictive services that continuously adapt to user behavior. Information from devices, sensors and applications around us will drive services seamlessly across mobile and fixed devices/infrastructure. This evolution is happening now in software defined services and secure networking. Four key drivers – Performance, Economics, Interoperability and Trust ...
Financial Technology has become a topic of intense interest throughout the cloud developer and enterprise IT communities. Accordingly, attendees at the upcoming 20th Cloud Expo at the Javits Center in New York, June 6-8, 2017, will find fresh new content in a new track called FinTech.
@DevOpsSummit at Cloud taking place June 6-8, 2017, at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long developm...
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 20th Cloud Expo, which will take place on June 6-8, 2017 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 add...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
Bert Loomis was a visionary. This general session will highlight how Bert Loomis and people like him inspire us to build great things with small inventions. In their general session at 19th Cloud Expo, Harold Hannon, Architect at IBM Bluemix, and Michael O'Neill, Strategic Business Development at Nvidia, discussed the accelerating pace of AI development and how IBM Cloud and NVIDIA are partnering to bring AI capabilities to "every day," on-demand. They also reviewed two "free infrastructure" pr...
SYS-CON Events announced today that Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Juniper Networks challenges the status quo with products, solutions and services that transform the economics of networking. The company co-innovates with customers and partners to deliver automated, scalable and secure network...
The age of Digital Disruption is evolving into the next era – Digital Cohesion, an age in which applications securely self-assemble and deliver predictive services that continuously adapt to user behavior. Information from devices, sensors and applications around us will drive services seamlessly across mobile and fixed devices/infrastructure. This evolution is happening now in software defined services and secure networking. Four key drivers – Performance, Economics, Interoperability and Trust ...
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
Cloud Expo, Inc. has announced today that Aruna Ravichandran, vice president of DevOps Product and Solutions Marketing at CA Technologies, has been named co-conference chair of DevOps at Cloud Expo 2017. The @DevOpsSummit at Cloud Expo New York will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and @DevOpsSummit at Cloud Expo Silicon Valley will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
Translating agile methodology into real-world best practices within the modern software factory has driven widespread DevOps adoption, yet much work remains to expand workflows and tooling across the enterprise. As models evolve from pockets of experimentation into wholescale organizational reinvention, practitioners find themselves challenged to incorporate the culture and architecture necessary to support DevOps at scale. In his session at @DevOpsSummit at 20th Cloud Expo, Anand Akela, Senior...